gpu-orchestration

(3)
Company
TensorPool
Ai · Developer Tools · Saas

TensorPool

TensorPool (YC W25) is a San Francisco startup that turns cloud GPUs into a git-style command line. Instead of wrestling with SSH sessions, provider dashboards, and idle-instance billing, machine learning engineers describe a training job in a config file and run 'tp job push' - TensorPool spins up a multi-node cluster across partner clouds, streams logs, saves outputs, and shuts everything down, billing only for runtime. It advertises GPU access at roughly half the cost of major cloud providers, with H100s starting around $1.99/hr. Founded by three Stanford dormmates, the company was accepted into Y Combinator's Winter 2025 batch.

gpu-cloud · on-demand-gpuRead →
Company
Featherless AI
Ai · Developer Tools · Saas

Featherless AI

Featherless AI is a serverless inference platform that gives developers and enterprises a single API key to run more than 40,000 open-weight AI models across language, vision, audio and multimodal tasks - without provisioning or managing any GPUs. Founded in 2023 by the team behind the RWKV open-source model architecture, the company sells flat-rate subscriptions with unlimited tokens and positions itself as a neutral infrastructure layer for open-source AI, independent of the major cloud hyperscalers. It raised a $20M Series A in April 2026 co-led by AMD Ventures and Airbus Ventures, bringing total funding to about $25M.

featherless-ai · serverless-inferenceRead →
Company
Tamarind Bio
Ai · Health · Saas

Tamarind Bio

Tamarind Bio is a San Francisco software company building cloud infrastructure that lets bench scientists run 250+ AI and physics-based models for drug discovery - tools like AlphaFold, RFdiffusion, ProteinMPNN and GROMACS - through a no-code web interface and API, without managing GPUs, data pipelines or DevOps. Founded in 2023 by Stanford computer scientist Deniz Kavi and Sherry Liu, the company serves over 10,000 scientists, including 8 of the top 20 pharmaceutical companies, and raised a $13.6M Series A in February 2026.

protein-design · drug-discoveryRead →